drug

taurolidine and heparin

1 story · latest Aug 13, 2026

Status: FDA approved Nov 2023 · NDA214520
Brand: Defencath

Relationships

Developed by CorMedix Inc.

Timeline

CorMedix reports Q2 2026 results, flags REZZAYO filing and DefenCath supply deal

Aug 13Quarterly updateCorMedix Inc.rezafungin

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.